- Business
- Vinergy Capital Inc. (CSE:VIN, OTCQB:VNNYF), formerly known as Vanguard Investments Corp. and incorporated on March 20, 2001 under the Alberta Business Corporations Act with headquarters at Suite 1600, 409 Granville Street, Vancouver, British Columbia, V6C 1T2, Canada, operates as an investment issuer focused on generating income and long-term capital appreciation through strategic investments in public and private companies, particularly in artificial intelligence technologies for healthcare and industrial applications; its portfolio includes equity stakes, debt securities, share purchase warrants, and subscription agreements in entities such as Netramark Holdings Inc., Treatment.com AI Inc., Verses AI Inc., Leef Brands Inc., Healthcare Accretion Group Inc. (49.33% ownership developing the MedMatrix AI platform for patient data optimization and revenue enhancement in U.S. healthcare providers), CWE European Holdings Inc. (hemp retail operations in Germany), Mentorhead Incorporated (doing business as Limmi, an FDA- and HIPAA-compliant AI platform for life sciences data analytics, drug discovery, and clinical efficiency tools), First Person Ltd. (functional mushrooms producer), and Algo8 Industrial AI Inc. (AI digital twins and automation solutions for process industries across India, UAE, UK, Netherlands, U.S., and Canada); the company targets control positions or active management involvement in investees with 1-5 year horizons, emphasizing quarterly valuation reviews using fair value methods including published market quotes for public shares and management judgments for private holdings. Recent developments include a name change to MedBright AI Investments Inc. effective November 7, 2023 with new CSE ticker MDAI (though filings reference ongoing VIN usage), a shift from prior cannabis and digital currency strategies to AI-centric investments, subscription for 4,500,000 shares in Algo8 for $900,000 in February 2025, realization of $1,117,682 gain on dispositions of public investments like Edge Total Intelligence, Verses AI Inc., and others during the year ended February 28, 2025 yielding total investment income of $2,072,932, impairment of loans and interests to Healthcare Accretion Group totaling approximately $1,043,895 plus additional $551,205, full impairment of Mentorhead and other level 3 private investments based on collectability uncertainties, termination of the Limmi intellectual property license and option agreement on August 15, 2024 with dissolution of related U.S. subsidiary Vinergy Licensing Corp., and partial sale of CWE stake amid Neural Therapeutics Inc.'s acquisition of 30.75% interest completed August 13, 2025; operations span Canada, U.S., Germany, and global AI/healthtech markets with fiscal year-end February 28.